Clinical experience with the combined use of lopinavir/ritonavir and rifampicin.
until further notice
SourceAids, 23, 7, (2009), pp. 863-865
Article / Letter to editor
Display more detailsDisplay less details
SubjectN4i 3: Poverty-related infectious diseases; NCEBP 13: Infectious diseases and international health
Thirty-four patients treated concomitantly with lopinavir/ritonavir and rifampicin were evaluated. Overall, only 15% used the recommended increased dose of lopinavir/ritonavir. Of patients on a nonadjusted dose of lopinavir/ritonavir, 67% had a subtherapeutic lopinavir plasma concentration and 38% had a detectable viral load. Forty percent of patients on an increased dose of lopinavir/ritonavir prematurely stopped the drug combination because of adverse events. Combined use of lopinavir/ritonavir and rifampicin is challenging as it implies balancing between suboptimal efficacy and toxicity.
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.